

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Lampe, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP03/07824

Title: Antibacterial Ester Macrocycles

**MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

**FEE PAYMENT**

The Commissioner is authorized to charge Account No. 13-3372 in the amount of \$180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Barbara A. Shimei  
Reg. No.: 29,862  
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
Telephone: (203) 812-2786  
Facsimile: (203) 812-6459

Form PTO-1449 (Modified)		Department of Commerce Patent and Trademark Office		Serial No.		Filing Date Filed Herewith		Applicant(s): Lampe, et al.				
INFORMATION DISCLOSURE CITATION												
U.S. PATENT DOCUMENTS												
*		DOCUMENT NO.						DATE (MM/DD/YY)	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS												
*		DOCUMENT NO.						DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB-CLASS	TRANSLATION YES NO
	F1	2	8	0	1	5	9	1	01/06/01	FR		
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)												
	R1	Schmidt, et al., Total Synthesis of the Biphenomycins; III. <sup>1</sup> Synthesis of Biphenomycin B <sup>2</sup> , Synthesis, <u>10</u> : 1025-1030 (1992)										
	R2	Schmidt, et al., Total Synthesis of the Biphenomycins; V. <sup>1</sup> Synthesis of Biphenomycin A <sup>2</sup> , Synthesis, <u>12</u> : 1248-1254 (1992)										
	R3	Chang, et al., LL-AF283 Antibiotics, Cyclic Biphenyl Peptides, J. Antibiotics, <u>44(6)</u> : 674-677 (1991)										
	R4	Brown, et al., Application of the Suzuki Biphenyl Synthesis to the Natural Products Biphenomycin and Vancomycin, J. Chem. Soc. Perkin Trans. 1, <u>1</u> : 123-130 (1992)										
EXAMINER		/Noble Jarrell/ (01/09/2008)						DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./